{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:58:20Z","timestamp":1790996300577,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00702-023-02666-x","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T09:02:05Z","timestamp":1686992525000},"page":"631-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-0753","authenticated-orcid":false,"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"2666_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105357","volume":"109","author":"JE Ahlskog","year":"2023","unstructured":"Ahlskog JE (2023) Levodopa, homocysteine and Parkinson\u2019s disease: What\u2019s the problem? Parkinsonism Relat Disord 109:105357","journal-title":"Parkinsonism Relat Disord"},{"key":"2666_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.euroneuro.2010.04.010","volume":"20","author":"A Antonini","year":"2010","unstructured":"Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 20:683\u2013687","journal-title":"Eur Neuropsychopharmacol"},{"key":"2666_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/jnnp.58.3.293","volume":"58","author":"Y Ben Shlomo","year":"1995","unstructured":"Ben Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293\u2013299","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2666_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0972753120925560","volume":"26","author":"UA Bhosale","year":"2019","unstructured":"Bhosale UA, Yegnanarayan R, Agrawal A, Patil A (2019) Efficacy study of folic acid supplementation on homocysteine levels in adolescent epileptics taking antiepileptic drugs: a single blind randomized controlled clinical trial. Ann Neurosci 26:50\u201354","journal-title":"Ann Neurosci"},{"key":"2666_CR5","doi-asserted-by":"publisher","first-page":"9173","DOI":"10.1523\/JNEUROSCI.0125-12.2012","volume":"32","author":"T Bottiglieri","year":"2012","unstructured":"Bottiglieri T, Arning E, Wasek B, Nunbhakdi-Craig V, Sontag JM, Sontag E (2012) Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain. J Neurosci 32:9173\u20139181","journal-title":"J Neurosci"},{"key":"2666_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.18388\/abp.2004_3580","volume":"51","author":"JT Brosnan","year":"2004","unstructured":"Brosnan JT, Jacobs RL, Stead LM, Brosnan ME (2004) Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 51:405\u2013413","journal-title":"Acta Biochim Pol"},{"key":"2666_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.celrep.2015.02.048","volume":"10","author":"E Demicheva","year":"2015","unstructured":"Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O\u2019Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, Muller T, Calabresi PA, Schoemaker H, Mueller BK (2015) Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep 10:1887\u20131898","journal-title":"Cell Rep"},{"key":"2666_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ana.410350107","volume":"35","author":"DT Dexter","year":"1994","unstructured":"Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38\u201344","journal-title":"Ann Neurol"},{"key":"2666_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.55782\/ane-2007-1639","volume":"67","author":"J Dorszewska","year":"2007","unstructured":"Dorszewska J, Florczak J, Rozycka A, Kempisty B, Jaroszewska-Kolecka J, Chojnacka K, Trzeciak WH, Kozubski W (2007) Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer\u2019s and Parkinson\u2019s diseases. Acta Neurobiol Exp (wars ) 67:113\u2013129","journal-title":"Acta Neurobiol Exp (wars )"},{"key":"2666_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/0883073814551388","volume":"30","author":"RM El-Farahaty","year":"2015","unstructured":"El-Farahaty RM, El-Mitwalli A, Azzam H, Wasel Y, Elrakhawy MM, Hasaneen BM (2015) Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study. J Child Neurol 30:451\u2013457","journal-title":"J Child Neurol"},{"key":"2666_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamaneurol.2022.4193","volume":"80","author":"AJ Espay","year":"2023","unstructured":"Espay AJ, Okun MS (2023) Abandoning the Proteinopathy Paradigm in Parkinson Disease. JAMA Neurol 80:123\u2013124","journal-title":"JAMA Neurol"},{"key":"2666_CR12","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"2666_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0014-5793(89)81391-2","volume":"247","author":"Y Furukawa","year":"1989","unstructured":"Furukawa Y, Tomioka N, Sato W, Satoyoshi E, Hayashi K, Furukawa S (1989) Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett 247:463\u2013467","journal-title":"FEBS Lett"},{"key":"2666_CR14","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMe2213120","volume":"387","author":"D Galasko","year":"2022","unstructured":"Galasko D, Simuni T (2022) Lack of Benefit of Iron Chelation in Early Parkinson\u2019s Disease. N Engl J Med 387:2087\u20132088","journal-title":"N Engl J Med"},{"key":"2666_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/cells8050452","volume":"8","author":"F Guerra","year":"2019","unstructured":"Guerra F, Girolimetti G, Beli R, Mitruccio M, Pacelli C, Ferretta A, Gasparre G, Cocco T, Bucci C (2019) Synergistic effect of mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Cells 8:452","journal-title":"Cells"},{"key":"2666_CR16","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/advances\/nmab033","volume":"12","author":"F Hadtstein","year":"2021","unstructured":"Hadtstein F, Vrolijk M (2021) Vitamin B-6-induced neuropathy: exploring the mechanisms of pyridoxine toxicity. Adv Nutr 12:1911\u20131929","journal-title":"Adv Nutr"},{"key":"2666_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.expneurol.2005.04.008","volume":"195","author":"RA Hawkins","year":"2005","unstructured":"Hawkins RA, Mokashi A, Simpson IA (2005) An active transport system in the blood-brain barrier may reduce levodopa availability. Exp Neurol 195:267\u2013271","journal-title":"Exp Neurol"},{"key":"2666_CR18","first-page":"471","volume":"48","author":"W Herrmann","year":"2002","unstructured":"Herrmann W, Knapp JP (2002) Hyperhomocysteinemia: a new risk factor for degenerative diseases. Clin Lab 48:471\u2013481","journal-title":"Clin Lab"},{"key":"2666_CR19","first-page":"161","volume":"6","author":"M Hinz","year":"2014","unstructured":"Hinz M, Stein A, Cole T (2014) The Parkinson\u2019s disease death rate: carbidopa and vitamin B6. Clin Pharmacol 6:161\u2013169","journal-title":"Clin Pharmacol"},{"key":"2666_CR20","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.lfs.2005.02.014","volume":"77","author":"C Isobe","year":"2005","unstructured":"Isobe C, Murata T, Sato C, Terayama Y (2005) Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer\u2019s disease and Parkinson\u2019s disease. Life Sci 77:1836\u20131843","journal-title":"Life Sci"},{"key":"2666_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jocn.2009.09.034","volume":"17","author":"C Isobe","year":"2010","unstructured":"Isobe C, Abe T, Terayama Y (2010) L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson\u2019s disease. J Clin Neurosci 17:717\u2013721","journal-title":"J Clin Neurosci"},{"key":"2666_CR22","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","volume":"30","author":"A Jowaed","year":"2010","unstructured":"Jowaed A, Schmitt I, Kaut O, Wullner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson\u2019s disease patients\u2019 brains. J Neurosci 30:6355\u20136359","journal-title":"J Neurosci"},{"key":"2666_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.drudis.2018.08.001","volume":"23","author":"K Kalani","year":"2018","unstructured":"Kalani K, Yan SF, Yan SS (2018) Mitochondrial permeability transition pore: a potential drug target for neurodegeneration. Drug Discov Today 23:1983\u20131989","journal-title":"Drug Discov Today"},{"key":"2666_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12013-014-0006-5","volume":"70","author":"PK Kamat","year":"2014","unstructured":"Kamat PK, Kalani A, Kyles P, Tyagi SC, Tyagi N (2014) Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease. Cell Biochem Biophys 70:707\u2013719","journal-title":"Cell Biochem Biophys"},{"key":"2666_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1471-4159.2011.07313.x","volume":"118","author":"Y Kasai","year":"2011","unstructured":"Kasai Y, Tachikawa M, Hirose S, Akanuma S, Hosoya K (2011) Transport systems of serine at the brain barriers and in brain parenchymal cells. J Neurochem 118:304\u2013313","journal-title":"J Neurochem"},{"key":"2666_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175300","volume":"934","author":"M Khot","year":"2022","unstructured":"Khot M, Sood A, Tryphena KP, Khan S, Srivastava S, Singh SB, Khatri DK (2022) NLRP3 inflammasomes: A potential target to improve mitochondrial biogenesis in Parkinson\u2019s disease. Eur J Pharmacol 934:175300","journal-title":"Eur J Pharmacol"},{"key":"2666_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00702-011-0689-3","volume":"119","author":"F Klostermann","year":"2012","unstructured":"Klostermann F, Jugel C, M\u00fcller T, Marzinzik F (2012) Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 119:369\u2013372","journal-title":"J Neural Transm"},{"key":"2666_CR28","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1523\/JNEUROSCI.0084-17.2017","volume":"37","author":"JA Korecka","year":"2017","unstructured":"Korecka JA, Moloney EB, Eggers R, Hobo B, Scheffer S, Ras-Verloop N, Pasterkamp RJ, Swaab DF, Smit AB, van Kesteren RE, Bossers K, Verhaagen J (2017) Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson\u2019s disease. J Neurosci 37:9361\u20139379","journal-title":"J Neurosci"},{"key":"2666_CR29","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1021\/tx200082h","volume":"24","author":"EA Liedhegner","year":"2011","unstructured":"Liedhegner EA, Steller KM, Mieyal JJ (2011) Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson\u2019s disease. Chem Res Toxicol 24:1644\u20131652","journal-title":"Chem Res Toxicol"},{"key":"2666_CR30","doi-asserted-by":"crossref","unstructured":"Malouf R, Grimley EJ (2003) The effect of vitamin B6 on cognition. Cochrane Database Syst Rev CD004393","DOI":"10.1002\/14651858.CD004393"},{"key":"2666_CR31","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/mds.22807","volume":"24","author":"D Manca","year":"2009","unstructured":"Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, Melis M (2009) Reversible encephalopathy and axonal neuropathy in Parkinson\u2019s disease during duodopa therapy. Mov Disord 24:2293\u20132294","journal-title":"Mov Disord"},{"key":"2666_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2007.01.028","volume":"257","author":"E Martignoni","year":"2007","unstructured":"Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F (2007) Homocysteine and Parkinson\u2019s disease: a dangerous liaison? J Neurol Sci 257:31\u201337","journal-title":"J Neurol Sci"},{"key":"2666_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1568-1637(03)00013-8","volume":"2","author":"MP Mattson","year":"2003","unstructured":"Mattson MP (2003) Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res Rev 2:329\u2013342","journal-title":"Ageing Res Rev"},{"key":"2666_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000051275","volume":"12","author":"A McCaddon","year":"2001","unstructured":"McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C (2001) Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12:309\u2013313","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2666_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/ana.410080603","volume":"8","author":"E Melamed","year":"1980","unstructured":"Melamed E, Hefti F, Wurtman RJ (1980) Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8:558\u2013563","journal-title":"Ann Neurol"},{"key":"2666_CR36","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1038\/s41598-017-10987-7","volume":"7","author":"AJ Mothe","year":"2017","unstructured":"Mothe AJ, Tassew NG, Shabanzadeh AP, Penheiro R, Vigouroux RJ, Huang L, Grinnell C, Cui YF, Fung E, Monnier PP, Mueller BK, Tator CH (2017) RGMa inhibition with human monoclonal antibodies promotes regeneration, plasticity and repair, and attenuates neuropathic pain after spinal cord injury. Sci Rep 7:10529","journal-title":"Sci Rep"},{"key":"2666_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1301\/002966402320964089","volume":"60","author":"JW Miller","year":"2002","unstructured":"Miller JW (2002) Homocysteine, folate deficiency, and Parkinson\u2019s disease. Nutr Rev 60:410\u2013413","journal-title":"Nutr Rev"},{"key":"2666_CR38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1586\/14737175.8.6.957","volume":"8","author":"T M\u00fcller","year":"2008","unstructured":"M\u00fcller T (2008) Role of homocysteine in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 8:957\u2013967","journal-title":"Expert Rev Neurother"},{"key":"2666_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/14656566.2022.2045275","volume":"23","author":"T M\u00fcller","year":"2022","unstructured":"M\u00fcller T (2022) What are the main considerations when prescribing pharmacotherapy for Parkinson\u2019s disease? Expert Opin Pharmacother 23:745\u2013750","journal-title":"Expert Opin Pharmacother"},{"key":"2666_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","volume":"62","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson\u2019s disease patients. Eur J Clin Pharmacol 62:447\u2013450","journal-title":"Eur J Clin Pharmacol"},{"key":"2666_CR41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/mds.22482","volume":"24","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkinson\u2019s disease. Mov Disord 24:929\u2013932","journal-title":"Mov Disord"},{"key":"2666_CR42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/mds.26560","volume":"31","author":"T M\u00fcller","year":"2016","unstructured":"M\u00fcller T, Kohlhepp W (2016) Hypomethylation in Parkinson\u2019s disease: an epigenetic drug effect? Mov Disord 31:605","journal-title":"Mov Disord"},{"key":"2666_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mehy.2017.10.030","volume":"110","author":"T M\u00fcller","year":"2018","unstructured":"M\u00fcller T, Kohlhepp W (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson\u2019s disease. Med Hypotheses 110:46\u201349","journal-title":"Med Hypotheses"},{"key":"2666_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.29365","volume":"38","author":"T M\u00fcller","year":"2023","unstructured":"M\u00fcller T, Kuhn W (2023) Epigenetic drug effects in levodopa-treated patients with Parkinson\u2019s disease. Mov Disord 38:710\u2013711","journal-title":"Mov Disord"},{"key":"2666_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00702-009-0275-0","volume":"116","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller T, Muhlack S (2009) Peripheral COMT inhibition prevents levodopa associated homocysteine increase. J Neural Transm (vienna ) 116:1253\u20131256","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR46","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","volume":"16","author":"T M\u00fcller","year":"2010","unstructured":"M\u00fcller T, Muhlack S (2010) Acute homocysteine rise after repeated levodopa application in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 16:688\u2013689","journal-title":"Parkinsonism Relat Disord"},{"key":"2666_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","volume":"354","author":"T M\u00fcller","year":"1999","unstructured":"M\u00fcller T, Werne B, Fowler B, Kuhn W (1999) Nigral endothelial dysfunction, homocysteine, and Parkinson\u2019s disease. Lancet 354:126\u2013127","journal-title":"Lancet"},{"key":"2666_CR48","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archneur.61.5.657","volume":"61","author":"T M\u00fcller","year":"2004","unstructured":"M\u00fcller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657\u2013660","journal-title":"Arch Neurol"},{"key":"2666_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/01.wnf.0000183447.58529.79","volume":"28","author":"T M\u00fcller","year":"2005","unstructured":"M\u00fcller T, Lang UE, Muhlack S, Welnic J, Hellweg R (2005) Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. Clin Neuropharmacol 28:238\u2013240","journal-title":"Clin Neuropharmacol"},{"key":"2666_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00702-011-0614-9","volume":"118","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011a) Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel. J Neural Transm 118:1329\u20131333","journal-title":"J Neural Transm"},{"key":"2666_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/mds.23384","volume":"26","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T, Muhlack S (2011b) Cysteinyl-glycine reduction as marker for Levodopa induced oxidative stress in Parkinson\u2019s disease patients. Mov Disord 26:543\u2013546","journal-title":"Mov Disord"},{"key":"2666_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/WNF.0b013e318283fa18","volume":"36","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Jugel C, Muhlack S, Klostermann F (2013a) Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol 36:52\u201354","journal-title":"Clin Neuropharmacol"},{"key":"2666_CR53","doi-asserted-by":"crossref","unstructured":"M\u00fcller T, van LT, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013b) Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19: 501\u2013507","DOI":"10.1016\/j.parkreldis.2013.02.006"},{"key":"2666_CR54","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00702-014-1308-x","volume":"122","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T, Barghorn S, L\u00fctge S, Haas T, Mueller R, Gerlach B, \u00d6hm G, Eilert K, Trommer I, Mueller BK (2015) Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neural Transm (vienna ) 122:841\u2013848","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00702-016-1519-4","volume":"123","author":"T M\u00fcller","year":"2016","unstructured":"M\u00fcller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson\u2019s disease. J Neural Transm (vienna ) 123:401\u2013406","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR56","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cells10040873","volume":"10","author":"T M\u00fcller","year":"2021","unstructured":"M\u00fcller T, Mueller BK, Riederer P (2021) Perspective: treatment for disease modification in chronic neurodegeneration. Cells 10:873","journal-title":"Cells"},{"key":"2666_CR57","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/cells11091511","volume":"11","author":"T M\u00fcller","year":"2022","unstructured":"M\u00fcller T, Schlegel E, Zingler S, Thiede HM (2022) Effects of one-day application of Levodopa\/Carbidopa\/Entacapone versus Levodopa\/Carbidopa\/Opicapone in Parkinson\u2019s disease patients. Cells 11:1511","journal-title":"Cells"},{"key":"2666_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","volume":"63","author":"MG Murer","year":"2001","unstructured":"Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog Neurobiol 63:71\u2013124","journal-title":"Prog Neurobiol"},{"key":"2666_CR59","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00702-023-02617-6","volume":"130","author":"T Nagatsu","year":"2023","unstructured":"Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K, Zucca FA, Zecca L, Youdim M, Wulf M, Riederer P, Dijkstra JM (2023) The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson\u2019s disease. J Neural Transm (vienna ) 130:611\u2013625","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","volume":"207","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sasaki K, Nakashima K (2003) Hypertrophy of IMC of carotid artery in Parkinson\u2019s disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207:19\u201323","journal-title":"J Neurol Sci"},{"key":"2666_CR61","first-page":"212","volume":"60","author":"M Naoi","year":"1993","unstructured":"Naoi M, Dostert P, Yoshida M, Nagatsu T (1993) N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv Neurol 60:212\u2013217","journal-title":"Adv Neurol"},{"key":"2666_CR62","first-page":"197","volume":"41","author":"M Naoi","year":"1994","unstructured":"Naoi M, Maruyama W, Niwa T, Nagatsu T (1994) Novel toxins and Parkinson\u2019s disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J Neural Transm Suppl 41:197\u2013205","journal-title":"J Neural Transm Suppl"},{"key":"2666_CR63","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.410430211","volume":"43","author":"M Naoi","year":"1998","unstructured":"Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS (1998) (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol 43:212\u2013216","journal-title":"Ann Neurol"},{"key":"2666_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125656","volume":"10","author":"G Ni","year":"2015","unstructured":"Ni G, Qin J, Li H, Chen Z, Zhou Y, Fang Z, Chen Y, Zhou J, Huang M, Zhou L (2015) Effects of antiepileptic drug monotherapy on one-carbon metabolism and DNA methylation in patients with epilepsy. PLoS ONE 10:e0125656","journal-title":"PLoS ONE"},{"key":"2666_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0304-3940(92)90738-S","volume":"144","author":"A Nitta","year":"1992","unstructured":"Nitta A, Furukawa Y, Hayashi K, Hiramatsu M, Kameyama T, Hasegawa T, Nabeshima T (1992) Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain. Neurosci Lett 144:152\u2013156","journal-title":"Neurosci Lett"},{"key":"2666_CR66","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archneur.61.6.865","volume":"61","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Bottiglieri T, az-Arrastia R (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61:865\u2013868","journal-title":"Arch Neurol"},{"key":"2666_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41419-021-03469-2","volume":"12","author":"W Oda","year":"2021","unstructured":"Oda W, Fujita Y, Baba K, Mochizuki H, Niwa H, Yamashita T (2021) Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease. Cell Death Dis 12:181","journal-title":"Cell Death Dis"},{"key":"2666_CR68","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0006-8993(94)90833-8","volume":"660","author":"E Oestreicher","year":"1994","unstructured":"Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8\u201318","journal-title":"Brain Res"},{"key":"2666_CR69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archneur.61.5.633","volume":"61","author":"P Ouilleabhain","year":"2004","unstructured":"Ouilleabhain P, az-Arrastia R (2004) Levodopa elevates homocysteine: is this a problem? Arch Neurol 61:633\u2013634","journal-title":"Arch Neurol"},{"key":"2666_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2408","volume":"11","author":"KAM Pauls","year":"2021","unstructured":"Pauls KAM, Toppila J, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E (2021) Polyneuropathy monitoring in Parkinson\u2019s disease patients treated with levodopa\/carbidopa intestinal gel. Brain Behav 11:e2408","journal-title":"Brain Behav"},{"key":"2666_CR71","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10522-006-9040-z","volume":"8","author":"I Picerno","year":"2007","unstructured":"Picerno I, Chirico C, Condello S, Visalli G, Ferlazzo N, Gorgone G, Caccamo D, Ientile R (2007) Homocysteine induces DNA damage and alterations in proliferative capacity of T-lymphocytes: a model for immunosenescence? Biogerontology 8:111\u2013119","journal-title":"Biogerontology"},{"key":"2666_CR72","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","volume":"63","author":"RB Postuma","year":"2004","unstructured":"Postuma RB, Lang AE (2004) Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 63:886\u2013891","journal-title":"Neurology"},{"key":"2666_CR73","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","volume":"66","author":"RB Postuma","year":"2006","unstructured":"Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66:1941\u20131943","journal-title":"Neurology"},{"key":"2666_CR74","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/mds.21085","volume":"21","author":"C Reitz","year":"2006","unstructured":"Reitz C, Trenkwalder C, Kretzschmar K, Roesler A, v Eckardstein A, Berger K, (2006) Relation of cerebral small-vessel disease and brain atrophy to mild parkinsonism in the elderly. Mov Disord 21:1914\u20131919","journal-title":"Mov Disord"},{"key":"2666_CR75","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Kr\u00fcger R, M\u00fcller T, Reichmann H, Riess O, Storch A, Strobel S, Van ET, Volker HU, Winkler J, Winklhofer KF, Wullner U, Zunke F, Monoranu CM (2019) alpha-Synuclein in Parkinson\u2019s disease: causal or bystander? J Neural Transm (Vienna) 126:815\u2013840","journal-title":"J Neural Transm (Vienna)"},{"key":"2666_CR76","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00702-021-02414-z","volume":"128","author":"P Riederer","year":"2021","unstructured":"Riederer P, Monoranu C, Strobel S, Iordache T, Sian-Hulsmann J (2021) Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson\u2019s disease. J Neural Transm (vienna ) 128:1577\u20131598","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR77","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00702-023-02630-9","volume":"130","author":"P Riederer","year":"2023","unstructured":"Riederer P, Nagatsu T, Youdim MBH, Wulf M, Dijkstra JM, Sian-Huelsmann J (2023) Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson\u2019s disease. J Neural Transm (vienna ) 130:627\u2013646","journal-title":"J Neural Transm (vienna )"},{"key":"2666_CR78","doi-asserted-by":"publisher","DOI":"10.1021\/bi9018658","author":"EA Sabens","year":"2010","unstructured":"Sabens EA, Distler AM, Mieyal JJ (2010) Levodopa deactivates enzymes that regulate Thiol-Disulfide homeostasis and promotes neuronal cell death - implications for therapy of Parkinson\u2019s disease. Biochemistry. https:\/\/doi.org\/10.1021\/bi9018658","journal-title":"Biochemistry"},{"key":"2666_CR79","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.pnpbp.2005.06.026","volume":"29","author":"PS Sachdev","year":"2005","unstructured":"Sachdev PS (2005) Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry 29:1152\u20131161","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2666_CR80","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/mds.25112","volume":"27","author":"RS Schwartz","year":"2012","unstructured":"Schwartz RS, Halliday GM, Cordato DJ, Kril JJ (2012) Small-vessel disease in patients with Parkinson\u2019s disease: a clinicopathological study. Mov Disord 27:1506\u20131512","journal-title":"Mov Disord"},{"key":"2666_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jocn.2018.10.029","volume":"58","author":"RS Schwartz","year":"2018","unstructured":"Schwartz RS, Halliday GM, Soh D, Cordato DJ, Kril JJ (2018) Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson\u2019s disease. J Clin Neurosci 58:70\u201374","journal-title":"J Clin Neurosci"},{"key":"2666_CR82","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994a) Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348\u2013355","journal-title":"Ann Neurol"},{"key":"2666_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/ana.410360306","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994b) Glutathione-related enzymes in brain in Parkinson\u2019s disease. Ann Neurol 36:356\u2013361","journal-title":"Ann Neurol"},{"key":"2666_CR84","doi-asserted-by":"crossref","unstructured":"Sian-H\u00fclsmann J, Riederer P (2021) The Nigral Coup in Parkinson's disease by alpha-Synuclein and its associated rebels. Cells 10","DOI":"10.3390\/cells10030598"},{"key":"2666_CR85","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/STROKEAHA.122.038640","volume":"53","author":"JD Spence","year":"2022","unstructured":"Spence JD, Hankey GJ (2022) Problem in the recent american heart association guideline on secondary stroke prevention: B Vitamins to lower homocysteine do prevent stroke. Stroke 53:2702\u20132708","journal-title":"Stroke"},{"key":"2666_CR86","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1474-4422(17)30180-1","volume":"16","author":"JD Spence","year":"2017","unstructured":"Spence JD, Yi Q, Hankey GJ (2017) B vitamins in stroke prevention: time to reconsider. Lancet Neurol 16:750\u2013760","journal-title":"Lancet Neurol"},{"key":"2666_CR87","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/archneurol.2009.195","volume":"66","author":"CM Tanner","year":"2009","unstructured":"Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW (2009) Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 66:1106\u20131113","journal-title":"Arch Neurol"},{"key":"2666_CR88","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1289\/ehp.1002839","volume":"119","author":"CM Tanner","year":"2011","unstructured":"Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW (2011) Rotenone, paraquat, and Parkinson\u2019s disease. Environ Health Perspect 119:866\u2013872","journal-title":"Environ Health Perspect"},{"key":"2666_CR89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom10081119","volume":"10","author":"A Tawfik","year":"2020","unstructured":"Tawfik A, Samra YA, Elsherbiny NM, Al-Shabrawey M (2020) Implication of Hyperhomocysteinemia in Blood Retinal Barrier (BRB) dysfunction. Biomolecules 10:119. https:\/\/doi.org\/10.3390\/biom10081119","journal-title":"Biomolecules"},{"key":"2666_CR90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ana.22021","volume":"68","author":"C Toth","year":"2010","unstructured":"Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28\u201336","journal-title":"Ann Neurol"},{"key":"2666_CR91","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220449","author":"KP Tryphena","year":"2022","unstructured":"Tryphena KP, Anuradha U, Kumar R, Rajan S, Srivastava S, Singh SB, Khatri DK (2022) Understanding the involvement of microRNAs in mitochondrial dysfunction and their role as potential biomarkers and therapeutic targets in Parkinson\u2019s disease. J Alzheimers Dis. https:\/\/doi.org\/10.3233\/JAD-220449","journal-title":"J Alzheimers Dis"},{"key":"2666_CR92","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","volume":"11","author":"P Valkovic","year":"2005","unstructured":"Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P (2005) Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients. Parkinsonism Relat Disord 11:253\u2013256","journal-title":"Parkinsonism Relat Disord"},{"key":"2666_CR93","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"2666_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105920","volume":"175","author":"RM Wise","year":"2022","unstructured":"Wise RM, Wagener A, Fietzek UM, Klopstock T, Mosharov EV, Zucca FA, Sulzer D, Zecca L, Burbulla LF (2022) Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson\u2019s disease and Neurodegeneration with Brain Iron Accumulation disorders. Neurobiol Dis 175:105920","journal-title":"Neurobiol Dis"},{"key":"2666_CR95","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00415-005-0022-x","volume":"253","author":"A Wong","year":"2006","unstructured":"Wong A, Mok V, Fan YH, Lam WW, Liang KS, Wong KS (2006) Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J Neurol 253:441\u2013447","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"2666_CR96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jnc.13646","volume":"139","author":"U W\u00fcllner","year":"2016","unstructured":"W\u00fcllner U, Kaut O, deBoni L, Piston D, Schmitt I (2016) DNA methylation in Parkinson\u2019s disease. J Neurochem 139(Suppl 1):108\u2013120","journal-title":"J Neurochem"},{"key":"2666_CR97","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/jnr.10314","volume":"69","author":"WQ Zhao","year":"2002","unstructured":"Zhao WQ, Williams Z, Shepherd KR, Reuben JS, Lee ES, Rling-Reed S, Lamango N, Soliman KF, Charlton CG (2002) S-adenosyl-methionine-induced apoptosis in PC12 cells. J Neurosci Res 69:519\u2013529","journal-title":"J Neurosci Res"},{"key":"2666_CR98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157016106777698414","volume":"4","author":"S Zoccolella","year":"2006","unstructured":"Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P (2006) Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr Vasc Pharmacol 4:237\u2013243","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:06:02Z","timestamp":1718985962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2666"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02666-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}